# Factors Associated With Liver Steatosis In Chronic Hepatitis C Patients

Thesis
Submitted for partial fulfillment of the Master degree in Tropical
Medicine

## BY Ahmed Mohamed Yaseen

(M.B.B.Ch Cairo University)

Under the Supervision of

## Dr. Hanan Abd El Haleem Marzouk.

Assistant Professor of Tropical Medicine Faculty of Medicine Cairo University

# Dr. Mohamed Mohamed Tawfik.

Assistant Professor of Tropical Medicine Faculty of Medicine Beni Suef University

# Dr. Olfat Gamil Shaker.

Professor of Medical Biochemistry
Faculty of Medicine
Cairo University

Faculty of Medicine Cairo University 2006

# ACKNOLEGMENT

"He, and will always be, Allah who always blessed my work and who sent me those who were of help "

I would like to thank ALLAH a lot for his kindness, patience and strength he gave to me to achieve this work and made me able to finish it.

I wish to express my sincere gratitude to **Dr. Hanan Abdel**Haleem Marzouk, Assistant professor of Tropical Medicine,
Faculty of Medicine, Cairo University. She patiently gave me
much of her time, experience, knowledge, directions, supervision
and support that can not be expressed by words. From her, I
learnt the way of scientific research.

My great appreciation and thanks are for **Dr. Mohammed**Mohammed Tawfik, Assistant professor of Tropical Medicine,
Faculty of Medicine, Beni Suef University, for his continuous
advice through this work.

I am so grateful to **Dr. Olfat Gameel Shaker**, Professor of Medical Biochemistry, Cairo University who gave me much of her support.

Words stand short to express my deep appreciation for the staff members of the Tropical Medicine Department and my colleagues by whom all, I was very much impressed by the noble characters, generous attitude and kind sympathy.

Special thanks to Bilharzial Liver Unit and Dr. Gamal Esmat Professor of Tropical Medicine, Faculty of Medicine, Cairo University and the director of the unit who provided us with financial and scientific support.

My great appreciation are for **Dr. Rasha Ahmed** lecturer of Tropical Medicine, Faculty of Medicine, Cairo University, for her continuous advice through this work.

I also thank **Dr.Sahar Talaat**, Assistant professor of pathology, Faculty of Medicine, Cairo University, who was of great help for this study.

I am much grateful to **Dr. Wafaa El Akel** for her great help for this study.

Ahmed Yasin

# **Table of Contents**

		Page
Acknowled	gment	
Introductio	on	1
Acknowledgment Introduction Aim of work The Review Chapter 1 : Steatosis in chronic hepatitis c  Chapter 2 : Insulin Resistance Chapter 3 : Leptin Chapter 4 : HCV-related steatosis and anti viral therapy Chapter 5 : Other causes of hepatic steatosis (I)Alcoholic steatosis (I) Non alcoholic fatty liver disease chapter 6 : Hepatitis C and Nonalcoholic fatty liver disease  Patients and Methods Results.  Discussion Summary and Conclusions.  References	3	
The Reviev	v	
Chapter 1	: Steatosis in chronic hepatitis c	4
Chapter 2	:Insulin Resistance	23
Chapter 3	: Leptin	43
Chapter 4	: HCV-related steatosis and anti viral therapy	57
Chapter 5	: Other causes of hepatic steatosis	
(I)Alco	pholic steatosis	61
(II) No	on alcoholic fatty liver disease	69
chapter 6	: Hepatitis C and Nonalcoholic fatty liver disease	77
Patients an	d Methods	85
Results		93
Discussion		113
Summary and Conclusions		126
Recommendations.		128
References		130
Arabic Sun	nmary	

### List of abbreviations

**ALD:** Alcoholic Liver Disease

**A2M:** Alfa 2 Macroglobulin

**ALP**: Alkaline phosphatase

**ALT:** Alanine transaminase

**Apo:** Apolipoprotein

**AST:** Aspartate transaminase

**ATP:** Adenosine Triphosphate

**BMI:** Body Mass Index

**CAGE:** Cut down, Annoyed, Guilty and Eye opene

**CPT –1:** Cytoplasm Transfer Protein 1

**DM:** Diabetes Mellitus

**EGr-1**: Early Growth response-1 transfer factor

**EIISA:** Enzyme Linked Immune Assay

**GGT:** Gamma Glutamyl Transferase

**3GP:** Glycerol 3 Phosphate

**HAI:** Histologic activity index

**HBV:** Hepatitis B virus

**HCV:** Hepatitis C virus

**HCC:** Hepatocellular carcinoma

**H&E:** Haematoxyline and Eosin

**HDL:** High Density Lipoprotein

**HIV:** Human immune deficiency virus

**HOMA:** Homeostasis Model Assessment Method

**HPG:** Hexose Phosphate Glutamyl Transferase

**IFN:** Interferon

**IL-:** Interleukin

**IR:** Insulin Resistance

**LFTs:** Liver Function Tests

MRI Magnetic resonance imaging

**MTP:** Microsomal Triglyceride Transfer Protein

**NAD:** Nicotinamide Adenine Dinucleotide

**NADH:** Reduced form of NAD

**NAFLD:** Non Alcoholic Fatty Liver Disease

**NASH:** Non Alcoholic Steatohepatitis

**NHW:** Non Hispanic World

**NIH:** National Institute of Health

**Ob:** Obesity

**OB-R:** Obesity Receptor

**OR:** Odd Ratio

**PCR:** Polymerase chain reaction

**PEG:** Pegylated

**PEG-OB:** Pegylated recombinant native human leptin

**RNA:** Ribonucleic acid

**SR:** Sustained Response

**TGF:** Transforming growth factor

**TGs:** Triglycerides

**TNF:** Tumor necrosis factor

U/S: Ultrasonography

**VLDL:** Very Low Density Lipoprotein

**WHO:** World Health Organization

# List of tables

### A-Tables of the review and methods

		Page
Table (1)	Histological features of steatosis and steatohepatitis.	5
Table (2)	Possible Mechanisms of HCV-Induced Steatosis.	10
Table (3)	Laboratory abnormalities in ALD.	65
Table (4)	Treatment options for NASH and NAFL.	76
Table (5)	ATP III Criteria for Metabolic Syndrome.	78
Table (6)	Modified HAI grading: necroinflammatory score.	89
Table (7)	Modified HAI grading: fibrosis score.	90

### **B-Tables of the results**

Table (1)	Demographic features of the studied groups.	99
Table (2)	The clinical presentation of the studied patients.	100
Table (3)	The Body Mass Index (B.M.I) of the studied groups .	1.7
Table (4)	The liver functions of the studied groups.	1.4
Table (5)	The lipid profile of the studied groups.	1 • £
Table (6)	The fasting blood sugar, serum leptin and insulin resistance of the studied groups.	1.0
Table (7)	Abdominal U/S findings in the studied groups.	١٠٦
Table (8)	Distribution of steatosis in the studied patients.	1.4
Table (9)	Histopathology of the liver biopsies of the studied patients as assessed by modified Knodell score (Modified HAI scoring system).	1.4
<b>Table (10)</b>	Nonparametric Correlations (Spearman correlation).	1.9
<b>Table (11)</b>	Logistic regression analysis.	117
<b>Table (12)</b>	Correlation between fibrosis, leptin and IR (Spearman correlation).	117

.

# List of figures

## A-Figures of the review

		Page
Fig. (1)	The histologic appearance of hepatic fatty change.	4
Fig. (2)	The natural history of HCV infection.	7
Fig. (3)	Hepatic histology in subjects with HCV and NAFLD.	80

## **B-Figures of the results**

101
102
103
104
105
106
107
-

Fig. (9)	Correlation between steatosis grade and age of the	110
	patients.	
Fig. (10)	Correlation between steatosis grade and BMI.	110
Fig. (11)	Correlation between steatosis grade and TGs level.	111
Fig. (12)	Correlation between steatosis grade and fibrosis stage.	111

### **ABSTRACT:**

#### **Background:**

Liver steatosis is a common finding in patients infected with hepatitis C virus (HCV). Host and viral factors have been associated with steatosis, but their relative contributions have not been clearly addressed. It has been suggested that steatosis plays a role in the progression of liver fibrosis.

#### Aim:

To assess factors associated with steatosis in Egyptian patients with chronic HCV infection and to assess the impact of insulin resistance levels (as HOMA score) and Leptin levels on liver steatosis, relative to other factors.

#### Patients and methods:

This study was conducted on fifty five cases of chronic HCV hepatitis as well as fifteen healthy subjects without evidence of chronic liver disease. They were clinically assessed and investigated ( <u>Laboratory</u> including complete blood count, liver biochemical profile, lipid profile, fasting blood glucose, serum insulin, HOMA IR and serum leptin, <u>imaging</u> by abdominal ultrasonography and <u>Histopathologically</u> according to modified Knodell score ). Body mass index was assessed. Logistic regression and multivariate analysis were used to identify variables independently associated with steatosis.

#### **Results:**

The frequency of hepatic steatosis was 54.5%. In univariate analysis, steatosis was associated with elevated BMI (P= 0.007), age (P= 0.008), high serum triglycerides (P= 0.005) and high fibrosis stage (P= 0.03). Multivariate analysis revealed that BMI is a good predictor for steatosis ( $\beta$ = 0.13 , P=0.04) while age and triglyceride are no more predictors (P= 0.06 and 0.09 respectively). Serum leptin was significantly higher in chronic HCV patients with steatosis than control group (17.05±17.69 ng/ml vs 7.44±7.95 ng/ml in the control group, P value <0.02 ). Serum leptin level in Chronic HCV patients with steatosis was relatively higher than Chronic HCV patients without steatosis, but the difference did not reach a statistical significance. There was no statistically significant difference between the studied groups as regard fasting blood sugar, serum insulin and insulin resistance.

### **Conclusion:**

Hepatic steatosis is common in patients with chronic HCV hepatitis. Factors associated with hepatic steatosis are BMI, age of the patient, serum TGs and stage of fibrosis. BMI is the only predictor of hepatic steatosis. There is no significant correlation between IR, leptin and incidence of hepatic steatosis.

### **Key Words:**

Liver steatosis
Hepatitis C patients
Insulin resistance

### Introduction

Hepatitis C virus infection is characterized by a high rate of developing chronic disease (observed in 75-85% of patients) and exposes the patient to the risk of chronic active hepatitis with progression to cirrhosis and hepatocellular carcinoma. Cirrhosis develops in about 25% of patients. (WHO,2002).

Steatosis was recently identified as a risk factor for progression to extensive fibrosis (*Cholet et al.,2004*). Liver steatosis is a common finding in patients infected with hepatitis C virus (HCV). Host and viral factors have been associated with steatosis, but their relative contributions have not clearly addressed (*Gordon et al.,2005*). Pathology studies show that from 40-86% of HCV infected patients will develop liver steatosis (*Mihm et al., 1997*). Several studies have demonstrated a significant relationship between steatosis and elevated Body Mass Index (BMI) (*Monto et al.,2002*). In HCV infected patients ,when risk factors of steatosis such as obesity, dyslipidemia, alcohol ,diabetes or drugs are excluded, the high prevalence of steatosis persists suggesting that HCV itself may be a risk factor for steatosis (*Andinolfi et al.,2001*).

Two main mechanisms have been proposed to account for the high prevalence of steatosis in chronic hepatitis C. Firstly ,in patients infected with genotype 3, the degree of steatosis is correlated with the level of viral load, (*Adinolfi et al.*,2001) suggesting that HCV could alter fatty acid metabolism and/or export in hepatocytes (*Perlemuter*,2002). Secondly

١

type 2 diabetes and more generally insulin resistance is highly frequent in chronic HCV infection. Recently, *Fartoux et al.*,2005 concluded that insulin resistance is the cause rather than the consequence of steatosis in genotype 1 patients and that increased circulating insulin is a risk factor for fibrosis through insulin resistance induced steatosis.

In chronic hepatitis C we need to clearly understand the basic pathophysiologic mechanisms involving potential viral polyprotein modulation of cellular lipid metabolism along with the relative contribution of body fat distribution, the anti oxidant system and possibly any genetic predisposition to the development of steatosis. Are there common links between the host, viral and other environmental factors that predispose to steatosis (Patel et al., 2003). One of such common links may be Leptin; a peptide which regulates food intake and energy expenditure. Leptin levels are increased in most cases of obesity, indicating Leptin insensitivity or resistance (Patel et al., 2003). Recent evidence suggests that Leptin promotes insulin resistance and alters insulin signaling leading to increased intracellular fatty acids. Furthermore, Leptin amplifies select proinflamatory responses (Loffreda et al., 1998) and mediates hepatic fibrogenesis during chronic liver injury. Romero Gomez et al.(2003) reported that increased serum leptin levels, higher degree of fibrosis and genotype 3 were independent variables associated with steatosis in patients with chronic HCV infection.